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2Abstract
The extensive projection of orexigenic neurons and the diffuse expression of orexin 
receptors suggest that endogenous orexins are involved in several physiological functions of 
the central nervous system, including learning and memory. Our previous study demonstrated 
that orexin A improves learning, consolidation and retrieval processes, which involves α- and 
β-adrenergic, cholinergic, dopaminergic, GABA-A-ergic, opiate and nitrergic 
neurotransmissions. However, we have little evidence about the action of orexin B on 
memory processes and the underlying neuromodulation. Therefore, the aim of the present 
study was to investigate the action of orexin B on passive avoidance learning and the 
involvement of neurotransmitters in this action in rats. Accordingly, rats were pretreated 
withthe selective orexin 2 receptor (OX2R) antagonist, EMPA; the γ-aminobutyric acid 
subunit A (GABA-A) receptor antagonist, the bicuculline; a D2, D3, D4 dopamine receptor 
antagonist, haloperidol; the nonselective opioid receptor antagonist, naloxone; the non-
specific nitric oxide synthase (NOS) inhibitor, nitro-L-arginine; the nonselective α-adrenergic 
receptor antagonist, phenoxybenzamine and the β-adrenergic receptor antagonist, propranolol. 
Our results demonstrate that orexin B can improve learning, consolidation of memory and 
retrieval. EMPA reversed completely the action of orexin B on memory consolidation. 
Bicuculline blocked fully; naloxone, nitro-L-arginine, phenoxybenzamine and propranolol 
attenuated the orexin B-induced memory consolidation, whereas haloperidol was ineffective. 
These data suggest that orexin B improves memory functions through OX2R and GABA-
ergic, opiate, nitrergic, α- and β-adrenergic neurotransmissions are also involved in this 
action.
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31. Introduction
The 33-amino acid orexin A (also known as hypocretin-1) and the 28-amino acid 
orexin B (also known as hypocretin-2) were described in the hypothalamus in 1998. Both 
neuropeptides are derived from the common precursor peptide (preproorexin) [1, 2]. Orexin-
expressing neurons are predominantly localized in the lateral hypothalamus area (LHA) and 
posterior hypothalamus and extensively project to the entire neuroaxis, including the cerebral 
cortex, olfactory bulb, thalamus, anterior and posterior hypothalamus, diagonal band of 
Broca, amygdala, hippocampus, bed nucleus of the stria terminalis, septum, brainstem and 
spinal cord [1-6].
Orexins activate at least two distinct G-protein coupled receptors, the orexin 1 receptor 
(OX1R) and the orexin 2 receptor (OX2R). OX1R has a tenfold greater affinity for orexin A 
than orexin B, whereas OX2R has nearly equal affinity for both neuropeptides [2, 7]. OX1R 
and OX2R are located on both pre- and post-synaptic processes, as well as on cell bodies [8, 
9]. Prominent expression of OX1R mRNA was found in the locus coeruleus (LC) and to a 
lesser extent in the dorsal raphe nucleus, hippocampal formation and tenia tecta. On the other 
hand, OX2R mRNA was identified mainly in the cerebral cortex, nucleus accumbens, 
paraventicular thalamic and subthalamic nuclei [10, 11].
The extensive projection of orexigenic neurons and the diffuse expression of orexin 
receptors suggest that endogenous orexins may be involved in several physiological functions
of the central nervous system (CNS), such as regulation of blood pressure [12, 13], body 
temperature [14], drinking behavior [15], food intake [2], nociception [16], sleep-waking 
cycle [17, 18], sleep disorder [19], reward and drug addiction [20], stress and arousal [21, 22], 
LH secretion [23, 24], prolactin secretion [25], and thyroid function [26]. The presence of 
numerous orexigenic terminals in the memory related brain regions, such as the hippocampus 
and amygdala suggests the involvement of orexins in learning and memory.
In our previous study, we have demonstrated that orexin A improves learning, 
consolidation and retrieval processes [27]. Several other studies provided further evidence 
about the memory enhancing action of orexin A [28, 29] and about the role of OX1R in 
memory [30-32]. In contrast, the effect of orexin B on memory processes has not been 
elucidated. Additionally, there are indications that the orexins might act as neurotransmitters 
per se or in concert with other monoaminergic structures [33, 34]. In our previous study, we 
demonstrated that a number of transmitters could be involved in the action of orexin A on 
memory consolidation [27]. However, we have little evidence about the underlying 
neuromodulation of the presumable effect of orexin B on learning and memory. Therefore, the 
4first aim of the present study was to investigate the action of orexin B on passive avoidance 
learning and memory formation in rats. The second aim of our study was to investigate the
involvement of neurotransmitters in mediating the action of orexin B on memory 
consolidation, thus the animals were pretreated with transmitter receptor antagonists prior to 
peptide administration.
2. Methods and Materials
2.1. Experimental animals and ethics statement
Male Wistar rats, weighing 150-250 g were used. The animals were maintained and 
treated during the experiments in accordance with the instructions of the Ethical Committee 
for the Protection of Animals in Research of the University of Szeged (Szeged, Hungary), 
which specifically approved this study. The rats were kept in their home cages at a constant 
temperature (23 ◦C) on a standard illumination schedule with 12-h light and 12-h dark periods 
(lights on from 6:00 AM). Commercial food and tap water were available ad libitum. To 
minimize the effects of nonspecific stress, the rats were handled daily. All surgery was 
performed under anesthesia, and all efforts were made to minimize suffering.
2.2. Surgery 
For intracerebroventricular (icv) administration, the rats were implanted with a 
stainless steel Luer canulla (10 mm long) aimed at the right lateral cerebral ventricle under 
Nembutal (35 mg/kg, intraperitoneally, ip) anesthesia. The stereotaxic coordinates were 0.2 
mm posterior; 1.7 mm lateral to the bregma; 3.7 mm deep from the dural surface, according to 
the atlas of Pellegrino et al., 1979 [35]. Cannulas were secured to the skull with dental cement 
and acrylate. The rats were used after a recovery period of 5 days.
2.3. Treatments
Orexin B and the selective OX2R antagonist EMPA (N-ethyl-2-[(6-methoxy-pyridin-
3-yl)-(toluene-2-sulphonyl)-amino]-N-pyridin-3-ylmethyl-acetamide) were purchased from 
Bachem Inc., Switzerland. Orexin B was applied via the icv cannula in a dose of 0.5 or 1.0 
µg/animal. For combined treatment, only 1.0 µg orexin B was used. Orexin B was 
administered 30 min before the learning trial (learning), after the learning trial (consolidation) 
and 30 min before the 24 h test (retrieval). EMPA was injected icv in a dose of 2.0, 4.0 or 8.0 
µg/animal.
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followed 30 min later by orexin B administration. 
The following receptor blockers were used: bicuculline methiodide (Sigma, St Louis, 
USA), 1 mg/kg ip; haloperidol (G. Richter Budapest, Hungary) 10 µg/kg ip; naloxone 
hydrochloride (Endo Lab., New York, USA), 0.3 mg/kg ip; nitro-L-arginine (N-w-nitro-L-
arginine, N-NA, Sigma-Aldrich, Budapest, Hungary), 10 µg/2 µl icv; phenoxybenzamine 
hydrochloride (Smith, Klein and French, Herts, UK), 2 mg/kg ip and propranolol 
hydrochloride (ICI, Macclesfield, UK), 10 mg/kg ip. The doses of the receptor blockers were 
selected on the basis of our earlier experience as being effective when administered with other 
neuropeptides, but not affecting the paradigm per se [27, 36].
2.4. Behavioral testing 
2.4.1. Passive avoidance test 
One-trial learning, step-through passive avoidance behavior was measured according 
to Ader et al., 1972 [37]. The apparatus consists of two separate chambers connected through 
a guillotine door. One of the chambers was illuminated, while the other was dark. Rats were 
placed on the illuminated platform and allowed to enter the dark compartment. Since rats
prefer dark to light, they normally entered within 5 s. Two additional trials were delivered on 
the following day. After the second trial, unavoidable mild electric footshocks (0.75 mA, 2 s) 
were delivered through the grid floor. The guillotine door was closed immediately after the rat 
entered the dark chamber and the animals could not escape the footshock. After this single 
trial, the rats were immediately removed from the apparatus and were treated. The 
consolidation of passive avoidance behavior was tested 24 h later. When the action of the 
peptide was tested on acquisition processes, the animals were treated before the single trial. 
When the action of the peptide was tested on retrieval processes the animals were treated with 
the peptide 30 min before the 24 h testing. For consolidation, the animals were treated with 
the peptide following the learning trial or first with the receptor antagonist and 30 min later 
with the peptide for combined treatment. In the 24 h testing each rat was placed on the 
platform and the latency to enter the dark compartment was measured up to a maximum of 
300 s.
2.5. Statistical analysis 
Statistical analysis of the behavioral testing was performed by two-way analysis of 
variance (two-way ANOVA), which was followed by Tukey’s post hoc comparison test. Only 
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figure captions. The differences between groups were examined by Tukey’s post hoc 
comparison test, and a probability level of 0.05 or less was accepted as indicating a 
statistically significant difference.
3. Results
The action of orexin B on learning was studied when the peptide was administered 30 
min prior to the learning trial. Orexin B lengthened significantly the latency of the avoidance 
response in the dose of 1 µg, whereas the 0.5 µg dose was ineffective [F(2, 53) = 4.87]; p < 
0.05 (Fig. 1). Thus orexin B facilitated the learning and consolidation in a dose-dependent 
manner.
The effect of orexin B on consolidation of the passive avoidance response was 
investigated when the peptide was given immediately following the learning trial. Orexin B 
lengthened significantly the latency of the passive avoidance response in the dose of 1 µg, 
while the dose of 0.5 µg was not effective [F(2, 88) = 6.03]; p < 0.01 (Fig. 2). Therefore 
orexin B facilitated the consolidation of the passive avoidance response in a dose-dependent 
manner.
EMPA alone in a dose of 2.0, 4.0, 8.0 µg did not change the passive avoidance 
learning, however in combination with orexin B (1 µg) blocked fully the orexin B-induced 
facilitation in consolidation of passive avoidance learning [F(5,54) = 4.84]; p < 0.05 (Fig. 3).
The action of orexin B on retrieval of passive avoidance learning was investigated 
when the peptide was administered 30 min before the 24-h test. Orexin B lengthened 
significantly the latency of the passive avoidance response in the dose of 1 µg, whereas the 
dose of 0.5 µg was ineffective [F(2, 39) = 4.08]; p < 0.05 (Fig. 4). Thus orexin B facilitated 
the retrieval of passive avoidance learning in a dose-dependent manner.
In the bicuculline-treated group, orexin B (1 µg/2 µl i.c.v.) facilitated the consolidation 
of passive avoidance learning [F(3,92) = 6.29]; p < 0.01. Bicuculline (1 mg/kg i.p.) itself had 
no action, while bicuculline pretreatment fully blocked the action of orexin B on this 
consolidation (Fig. 5).
In the naloxon-pretreated group, orexin B (1 µg/2 µl i.c.v.) facilitated the 
consolidation of passive avoidance learning [F(3,42) = 4.39]; p < 0.01. Naloxon (0.3 mg/kg 
i.p.) itself had no effect and attenuated but did not fully block the action of orexin B (Fig. 6).
In the nitro-L-arginine-treated group, orexin B (1 µg/2 µl i.c.v.) facilitated the 
consolidation of passive avoidance learning [F(3,81) = 4.19]; p < 0.01. Nitro-L-arginine (10 
7µg/2 µl i.c.v.) itself had no effect and attenuated but did not fully block the action of orexin B 
(Fig. 7).
In the phenoxybenzamine-treated group, orexin B (1 µg/2 µl i.c.v.) facilitated the 
consolidation of passive avoidance learning [F(3,41) = 4.56]; p < 0.01. Phenoxybenzamine (2 
mg/kg i.p.) itself had no effect and attenuated but did not fully block the action of orexin B 
(Fig. 8).
In the propranolol-pretreated group, orexin B (1 µg/2 µl i.c.v.) facilitated the 
consolidation of passive avoidance learning [F(3,64) = 5.44]; p < 0.01. Propranolol (10 mg/kg 
i.p.) itself had no effect and attenuated but did not fully block the action of orexin B (Fig. 9).
In the haloperidol-pretreated group, orexin B (1 µg/2 µl i.c.v.) facilitated the 
consolidation of passive avoidance learning [F(3,43) = 8.08]; p < 0.01. Haloperidol (10 µg/kg 
i.p.) itself had no effect and did not block the action of orexin B significantly (Fig. 10).
4. Discussion
Orexin A and orexin B are proteolytic derivates of a common precursor polypeptide 
(preproorexin) and activate 2 distinct G-protein coupled receptors (OX1R and OX2R). 
Orexin-producing neurons and orexin receptors are widely distributed in the entire neuraxis 
and involved in several physiological functions of the CNS, including learning and memory
[1-6]. Our previous study showed that orexin A is able to improve learning, consolidation of 
memory and retrieval processes in a passive avoidance paradigm in rats [27]. Other studies 
provided further evidence that orexin A can induce long-term potentiation (LTP) in the 
dentate gyrus in anesthetized rats [38] and could enhance memory in the mouse model of 
Alzheimer’s disease [28]. It has also been reported that OX1R play a prominent role in spatial 
learning and memory by using a selective OX1R antagonist (SB-334867-A) in rats [39]. The 
present study demonstrates for the first time that orexin B also can improve learning, 
consolidation of memory and retrieval in a passive avoidance paradigm in rats. This action is 
mediated through OX2R, since the selective OX2R antagonist EMPA reversed completely the 
orexin A-induced memory consolidation. EMPA alone in the doses used showed only a 
tendency to change the baseline learning, which may indicate that the endogenous orexin B is 
not involved prominently in the action described. The results of our previous study suggested 
that α- and β-adrenergic, dopaminergic, GABA-A-ergic, opioid receptors and nitrogen-
monoxide (NO) play role in the action of orexin A on consolidation of memory [27]. The 
results of the current study show that α- and β-adrenergic, GABA-A-ergic, opioid receptors 
and nitric oxide (NO) are involved in the effect of orexin B on consolidation of memory.
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mediation of physiologic memory processes [40] and in the pathogenesis of neurologic 
disorders, such as schizophrenia [41]. Several prior behavioral and biochemical studies 
revealed correlations between the GABA-ergic and the orexigenic systems. We have
demonstrated previously that GABA is involved in the mediation of the orexin A-induced 
memory consolidation in a passive avoidance test in rats [27]. Electrophysiological and 
histological investigations showed that orexigenic neurons of the LHA activate the GABA-
ergic neurons of the medial septum/diagonal band of Broca (MSDB) and increase the release 
of GABA locally via OXR2 [42]. MSDB, through its GABAergic and cholinergic projections 
to the hippocampus, modulates the hippocampal theta rhythm and associated learning and 
memory functions during exploratory behavior and REM sleep [42-44]. Additionally, intra-
CA1 infusion of orexin A increased the GABA and glutamate release in the hippocampus
[45]. On the other hand, optogenetic activation of GABA-ergic neurons in hypothalamic
preoptic area (POA) resulted in rapid inhibition of the orexigenic neurons of the LHA [46].
Our present study demonstrates for the first time that GABA-ergic neurotransmission is 
involved in the action of orexin B on memory consolidation since the selective GABA-A 
receptor antagonist, bicuculline blocked fully the foregoing consolidation. 
The adrenergic system is also important in memory functions. The primary source of 
forebrain norepinephrine (NE) is the LC, which is known to be implicated in attention and 
memory [47]. The highest density of orexin-fiber projections and OX1R are also found in 
noradrenergic neurons of the LC [5, 48]. An in vitro study showed that orexin B can increase 
the frequency of action potentials in rat and monkey brain slices containing the LC [34]. The 
hippocampus is one target of LC projections and also involved in learning and memory. It has 
been shown that adrenergic system can modulate different forms of synaptic plasticity in the 
hippocampus [49]. Though the hippocampus has a significant noradrenergic innervation, 
particularly in the dentate gyrus [50], it has only a modest orexigenic input [4, 6] and orexin 
receptor density [11]. In vitro studies revealed that intra-LC infusion of orexin A can produce 
NE-LTP in the dentate gyrus and NE release in the hippocampus in anesthetized rats [29]. 
Amygdala is implicated in the formation of emotional memory and represents another target 
of LC projections, along with a prominent orexigenic innervation and OX1R expression [32]. 
A recently published study demonstrated that the orexin fibers originating in the perifornical 
region of the hypothalamus directly depolarize LC neurons through rapid corelease of orexin 
and glutamate. The orexin activity in the LC, likely via OX1R, can drive NE signaling 
through β-adrenergic receptors in the lateral nucleus of the amygdala to enhance threat 
9memory formation [51]. Our present study demonstrates for the first time that both α- and β-
adrenergic neurotransmission is involved in the action of orexin B on memory consolidation 
since both the non-selective α-adrenergic receptor antagonist, phenoxybenzamine and the 
non-selective β-adrenergic receptor antagonist, propranolol attenuated this consolidation. 
The opioid system is also involved in memory as well as in reward and addiction [52]. 
Previous studies using OX1R and OX2R antagonists revealed that the orexigenic system is 
implicated in morphine withdrawal [53, 54]. On the other hand, investigations with opioid 
receptor antagonists showed that the action of orexin A on memory consolidation [27] or 
feeding [55] is mediated through opioid receptors. Our present study demonstrates for the first 
time that opioid neurotransmission is also involved in the action of orexin B on memory 
consolidation since both the µ and to a lesser extent δ and κ receptor antagonist naloxone 
attenuated this consolidation.
NO is another type of neurotransmitter which is associated with synaptic plasticity, 
learning and memory [56]. There is morphological evidence that NO interferes with orexins. 
NO and orexin-coexpressing neurons were identified in several nuclei of the hypothalamus, 
such as the arcuate, the dorsomedial, the ventromedial and the perifornical nuclei [57]. A prior 
study using nitro-L-arginine, a non-specific nitric oxide synthase (NOS) inhibitor revealed 
that NO participates in mediation of vasopressor/vasodepressor effects of orexin A and orexin 
B [58]. In addition, our previous study showed that NO plays role in the action of orexin A on 
memory consolidation as well [27]. Our present study demonstrates for the first time that 
nitrergic neurotransmission is also involved in the action of orexin B on memory 
consolidation since nitro-L-arginine attenuated the foregoing consolidation.
The mesolimbic dopaminergic system plays role in reward, drug addiction and 
memory [59]. It has been shown that dopaminergic and GABA-ergic neurons of the ventral 
tegmental area (VTA) receives orexigenic afferents from the LHA [60]. In vitro studies 
revealed that dopaminergic neurons of the VTA can be activated by both orexin A and B [61]. 
In vivo studies showed that intra-VTA administration of orexin A or orexin B enhances the 
release of dopamine in the nucleus accumbens (NAc) [62]. Our previous study showed that 
dopamine is involved in the mediation of the orexin A-induced memory consolidation in a 
passive avoidance test in rats [27]. Our present study demonstrates that dopaminergic 
neurotransmission may not be involved in the orexin B-induced consolidation of memory, as 
the D2, D3, D4 dopamine receptor antagonist, haloperidol did not block this consolidation. 
This observation can be interpreted by the differences between orexin A and orexin B in terms 
of mechanism of action in the VTA. On one hand, orexin A can increase the firing rate of 
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VTA GABA-ergic neurons, which may dampen the effect on dopaminergic neurons [63]. On
the other hand, the effect of orexin B is seems to be secondary to a direct control of the local 
glutamatergic neurotransmission in the VTA [64]. 
5. Conclusion
The present study demonstrates that orexin B can improve learning, consolidation of 
memory and retrieval in a passive avoidance paradigm in rats. Our results also show that α-
and β-adrenergic, GABA-ergic, nitrergic, and opiate neurotransmissions are involved in the 
orexin B-induced improvement in memory consolidation. 
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Figure legends
Fig. 1. The effects of different doses of orexin B on passive avoidance learning. The peptide 
was given 30 min before the learning trial. Orexin B (0.5 µg/2 µl, icv), orexin B (1.0 µg/2 µl, 
icv) *p < 0.05 vs. control. The mean and S.E. are shown. Numbers in brackets denote the 
numbers of animals used.
Fig. 2. The effects of different doses of orexin B on the consolidation of passive avoidance 
learning. The peptide was given immediately after the learning trial. Orexin B (0.5 µg/2 µl, 
icv), orexin B (1.0 µg/2 µl, icv) *p < 0.05 vs. control. The mean and S.E. are shown. Numbers 
in brackets denote the numbers of animals used.
Fig. 3. The effects of the selective OX2R antagonist, EMPA on orexin B-induced 
consolidation of passive avoidance learning. Orexin B (1.0 µg/2 µl, icv) *p < 0.05 vs. control, 
EMPA (2.0 µg/2 µl, icv), EMPA (4.0 µg/2 µl, icv), EMPA (8.0 µg/2 µl, icv), OreB 1.0 µg/2 
µl icv + EM 2.0 µg/2 µl icv. Abbreviations: OreB = orexin B, EM = EMPA. The mean and 
S.E. are shown. Numbers in brackets denote the numbers of animals used.
Fig. 4. The effects of different doses of orexin B on the retrieval of passive avoidance 
learning. The peptide was given 30 min before the 24-h testing. Orexin B (0.5 µg/2 µl, icv.), 
orexin B (1.0 µg/2 µl, icv) *p < 0.05 vs. control. The mean and S.E. are shown. Numbers in 
brackets denote the numbers of animals used.
Fig. 5. The effects of the γ-aminobutyric acid subunit A (GABA-A) receptor antagonist, 
bicuculline on orexin B-induced consolidation of passive avoidance learning. Orexin B (1.0 
µg/2 µl, icv) *p < 0.05 vs. control, bicuculline (1 mg/kg, ip), combined (bicuculline 1 mg/kg 
ip + orexin B 1.0 µg/2 µl, icv). The mean and S.E. are shown. Numbers in brackets denote the 
numbers of animals used.
Fig. 6. The effects of the nonselective opioid receptor antagonist, naloxone on orexin B-
induced consolidation of passive avoidance learning. Orexin B (1.0 µg/2 µl, icv) *p < 0.05 vs. 
control, naloxone (0.3 mg/kg, ip), combined (naloxone 0.3 mg/kg ip + orexin B 1.0 µg/2 µl, 
icv). The mean and S.E. are shown. Numbers in brackets denote the numbers of animals used.
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Fig. 7. The effects of the non-specific nitric oxide synthase (NOS) inhibitor, nitro-L-arginine 
on orexin B-induced consolidation of passive avoidance learning. Orexin B (1.0 µg/2 µl, 
i.c.v.) *p < 0.05 vs. control, nitro-L-arginine (10 µg/2 µl, icv), combined (nitro-L-arginine 10 
µg/2 µl icv + orexin B 1.0 µg/2 µl, icv). The mean and S.E. are shown. Numbers in brackets 
denote the numbers of animals used.
Fig. 8. The effects of the nonselective α-adrenergic receptor antagonist, phenoxybenzamine
on orexin B-induced consolidation of passive avoidance learning. Orexin B (1.0 µg/2 µl, 
i.c.v.) *p < 0.05 vs. control, phenoxybenzamine (2 mg/kg, ip), combined (phenoxybenzamine 
2 mg/kg, ip + orexin B 1.0 µg/2 µl, icv). The mean and S.E. are shown. Numbers in brackets 
denote the numbers of animals used.
Fig. 9. The effects of the β-adrenergic receptor antagonist, propranolol on orexin B-induced 
consolidation of passive avoidance learning. Orexin B (1.0 µg/2 µl, i.c.v.) *p < 0.05 vs. 
control, propranolol (10 mg/kg, ip), combined (propranolol 10 mg/kg, ip + orexin B 1.0 µg/2 
µl, icv). The mean and S.E. are shown. Numbers in brackets denote the numbers of animals 
used.
Fig. 10. The effects of the D2, D3, D4 dopamine receptor antagonist, haloperidol on orexin B-
induced consolidation of passive avoidance learning. Orexin B (1.0 µg/2 µl, i.c.v.) *p < 0.05 
vs. control, haloperidol (10 µg/kg, ip), combined (haloperidol 10 µg/kg, ip + orexin B 1.0 
µg/2 µl, icv). The mean and S.E. are shown. Numbers in brackets denote the numbers of 
animals used.
